I don't know the process in great detail but I would think once the EMA rules on the accelerated approval we should pretty quickly see the actual EMA filing be made.
New Reduce-it patents being in place before filing are going to be a great bonus for longevity of the patents in Europe.
(i) Rapporteurs’ recommendation on the request for accelerated assessment (top of Amarin): 1.) autologous CD34+ enriched cell fraction that contains CD34+ cells genetically modified ex vivo using a lentiviral vector encoding for the human arylsulfatase A(ARSA) cDNA sequence - Orphan - ATMP - H0005321 2.) valoctocogene roxaparvovec - ATMP - H0004749 3.) BALOXAVIR MARBOXIL - H0004974
(ii) The decision will be "published" by Friday (could be available earlier ???)
(iii) submission: Nov 11 (in case of Standard Review: could be Nov 25)
Best, G
ps.: I do not have a tin foil hat … Dr. and "Killer" are not the best business advisor ...